Both companies have a common goal of providing drug and device development services to clients, which are working on drug formulation and all phases of clinical trials in ocular pathologies, including glaucoma, dry eye, anti-inflammatory and age-related macular degeneration.
Drey Coleman, managing partner of Oculos, told Outsourcing-Pharma: “We exclusively do studies in the US and they’re in Europe – so for sponsors who want to perform global studies, we’ll be able to accommodate them now.”
She added that there’s currently a high demand for CROs that focus on ophthalmology, particularly for work with retinas, dry eye, glaucoma and post-operative studies.
“We have been exploring several opportunities to consolidate our presence in the US and Oculos appears to be a perfect partner for us at a stage where we are experiencing rapid growth,” said Pierre-Paul Elena, CEO of Iris Pharma. “We have a lot of confidence in Oculos’ wide range of quality services for ophthalmic drug and device development.”
This is Oculos’ first partnership, according to Coleman, who added that most of the clients the company serves are small and medium-sized biopharma companies.